Sunday - March 22, 2026

Category Archives: Services

Hemophilia Clinical Development Landscape Strengthens as 80+ Companies Drive Innovation | DelveInsight

Hemophilia Pipeline Prominent Hemophilia companies include Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others.   DelveInsight’s latest report, “Hemophilia Pipeline Insight, 2026” offers a … Continue reading →

HER2-Negative Breast Cancer Clinical Pipeline Witnesses Significant Growth as 70+ Companies Accelerate Therapeutic Innovation | DelveInsight

HER2-Negative Breast Cancer Clinical Trials HER2-Negative Breast Cancer companies include Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co., Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical … Continue reading →

Fuchs Endothelial Corneal Dystrophy Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Fuchs Endothelial Corneal Dystrophy Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Fuchs Endothelial Corneal Dystrophy pipeline landscape. It covers the Fuchs Endothelial Corneal Dystrophy pipeline drug profiles, including clinical and … Continue reading →

Breast Cancer Clinical Trial Gains Momentum: 250+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It … Continue reading →

Wet-Age Related Macular Degeneration Treatment Pipeline Shows Strong Momentum as 60+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Wet-AMD Pipeline Insight 2026” report provides comprehensive insights about 60+ companies and 75+ pipeline drugs in the Wet-AMD pipeline landscape. It covers the Wet-AMD Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet-AMD Pipeline … Continue reading →

Dravet Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight

DelveInsight’s, “Dravet syndrome Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Dravet syndrome pipeline landscape. It covers the Dravet Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Malignant Ascites Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

elveInsight’s, “Malignant Ascites Pipeline Insights 2026” Report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the Malignant Ascites pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Triple Negative Breast Cancer Clinical Trial Pipeline Expands as 165+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and … Continue reading →

High-Grade Glioma Treatment Pipeline Shows Strong Momentum as 150+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “High-Grade Glioma Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the High-Grade Glioma pipeline landscape. It covers the High-Grade Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight

DelveInsight’s “B-Cell Non-Hodgkin Lymphoma Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →